JF
AVTX icon

Jump Financial’s Avalo Therapeutics AVTX Stock Holding History

Jump Financial’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.73M Buy
201,902
+189,092
+1,476% +$2.99M 0.03% 625
2026
Q1 		$191K Sell
12,810
-282
-2% -$4.41K ﹤0.01% 1679
2025
Q4 		$238K Buy
+13,092
New +$221K ﹤0.01% 1663

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jump Financial's AVTX Position: Q2 2026 in Review

Jump Financial increased its Avalo Therapeutics (AVTX) stake by 1,476% in Q2 2026, buying an estimated $2.99M and bringing the position to 201,902 shares worth $3.73M. The position accounts for 0.03% of the portfolio, ranked #625.

Jump Financial first reported a position in AVTX in Q4 2025 and has held it in 3 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Jump Financial held 201,902 shares of Avalo Therapeutics worth $3.73M as of Q2 2026.
  • Jump Financial bought 189,092 Avalo Therapeutics shares in Q2 2026, an estimated $2.99M.
  • Avalo Therapeutics made up 0.03% of Jump Financial's portfolio in Q2 2026, its #625 holding.
  • Jump Financial first reported a position in Avalo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.